to imatinib – sold by Novartis as Glivec/Gleevec, but also available as a generic – on top of a reduced-intensity chemotherapy regimen in 230 patients with this type of leukaemia. According to ...

Find all the commercial and brand names of generic drug called Imatinib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

Get detailed information on Imatinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

By Bulto’s estimate, some 30% to 40% of first-line patients today are being treated with Gleevec or generic imatinib. Novartis expects the first adopters of Scemblix in first-line CML will be ...

The Intellectual Property Appellate Board of India has rejected Novartis' patent application for the anticancer drug Glivec (the β-crystalline form of imatinib mesylate) because it has not shown ...

Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary ...

Skinny labeling allows generic drug manufacturers to exclude ... $4.2 billion), and imatinib (Gleevec, Novartis; $3.1 billion). The authors caution that deterring the use of skinny labeling ...

Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or ...

Given that imatinib is well established as the frontline standard of care in patients with GIST, and that generic versions are available, imatinib represents a promising combination partner for ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...